X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA NOVARTIS AJANTA PHARMA/
NOVARTIS
 
P/E (TTM) x 20.7 284.5 7.3% View Chart
P/BV x 4.8 24.2 19.6% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 AJANTA PHARMA   NOVARTIS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
NOVARTIS
Mar-17
AJANTA PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,818855 212.6%   
Low Rs1,106666 166.2%   
Sales per share (Unadj.) Rs239.5219.0 109.3%  
Earnings per share (Unadj.) Rs52.819.1 276.4%  
Cash flow per share (Unadj.) Rs59.520.3 293.2%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs230.0307.0 74.9%  
Shares outstanding (eoy) m88.7729.96 296.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.13.5 175.9%   
Avg P/E ratio x27.739.8 69.6%  
P/CF ratio (eoy) x24.637.5 65.6%  
Price / Book Value ratio x6.42.5 256.7%  
Dividend payout %052.4 0.0%   
Avg Mkt Cap Rs m129,78222,779 569.8%   
No. of employees `0006.80.7 1,008.2%   
Total wages/salary Rs m3,7651,393 270.3%   
Avg. sales/employee Rs Th3,128.49,736.2 32.1%   
Avg. wages/employee Rs Th554.02,066.8 26.8%   
Avg. net profit/employee Rs Th689.7849.0 81.2%   
INCOME DATA
Net Sales Rs m21,2586,562 323.9%  
Other income Rs m242702 34.4%   
Total revenues Rs m21,4997,264 296.0%   
Gross profit Rs m6,584259 2,543.0%  
Depreciation Rs m59636 1,659.9%   
Interest Rs m47 56.9%   
Profit before tax Rs m6,226917 678.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,539345 446.0%   
Profit after tax Rs m4,686572 819.0%  
Gross profit margin %31.03.9 785.0%  
Effective tax rate %24.737.6 65.7%   
Net profit margin %22.08.7 252.8%  
BALANCE SHEET DATA
Current assets Rs m12,2369,731 125.7%   
Current liabilities Rs m3,4611,830 189.1%   
Net working cap to sales %41.3120.4 34.3%  
Current ratio x3.55.3 66.5%  
Inventory Days Days6049 123.7%  
Debtors Days Days8425 335.8%  
Net fixed assets Rs m11,14057 19,475.3%   
Share capital Rs m177141 125.7%   
"Free" reserves Rs m20,2379,056 223.5%   
Net worth Rs m20,4149,196 222.0%   
Long term debt Rs m100-   
Total assets Rs m24,48611,499 212.9%  
Interest coverage x1,519.4128.4 1,183.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.6 152.1%   
Return on assets %19.25.0 380.2%  
Return on equity %23.06.2 369.0%  
Return on capital %30.510.1 303.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,667129 9,051.4%   
Fx outflow Rs m1,6161,734 93.2%   
Net fx Rs m10,052-1,605 -626.3%   
CASH FLOW
From Operations Rs m2,854-380 -752.1%  
From Investments Rs m-2,6044,208 -61.9%  
From Financial Activity Rs m-2-3,318 0.1%  
Net Cashflow Rs m248510 48.6%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 1.6 2.0 77.5%  
FIIs % 7.6 1.6 475.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 21.5 79.1%  
Shareholders   20,968 41,647 50.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   DR. DATSONS LABS  STRIDES SHASUN LTD  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Cuts Losses; TCS Up 3%(Closing)

After opening the day in red, share markets in India witnessed volatile trading activity throughout the day but clawed back some gains in the final hours of the trading window.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jun 15, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS